BCL2L1 and non-small cell lung carcinoma: The use of trametinib increased BIM expression (by stabilizing BIM) in NSCLC cells that are buffered by either BCL-xL or MCL-1; thus, the cells became dependent on both BCL-xL and MCL-1 protein.